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Structure-based drug designAs there are more than 50 adenovirus serotypes, the likelihood of developing an effective vaccine is
low. Here we describe inhibitors of the adenovirus proteinase (AVP) with the ultimate objective of
developing anti-adenovirus agents. Inhibitors were identiﬁed via structure-based drug design using
as druggable sites the active site and a conserved cofactor pocket in the crystal structures of AVP. A
lead compound was identiﬁed that had an IC50 of 18 lM. One of eight structural derivatives of the
lead compound had an IC50 of 140 nM against AVP and an IC50 of 490 nM against the AVP with its
cofactor bound.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction of the Open Chemical Repository of the NCI Developmental Thera-Adenoviruses are major human pathogens that infect a wide
range of vertebrates, from hamsters to humans. They are the cause
of many, different acute infections, mostly in the respiratory and
gastrointestinal tracts, and conjunctivitis. (http://www.vmri.hu/
~harrach/AdVtaxlong.htm). Late in adenovirus infection, young
virions are assembled in part from precursor proteins. Of the 12
major virion proteins, 6 are precursor proteins. The penultimate
step before the appearance of infectious virus is the activation of
the adenovirus proteinase (AVP), a 23 kDa cysteine proteinase
[1,2], followed by the processing of the virion precursor proteins.
AVP is activated by two cofactors, pVIc (GVQSLKRRRCF) [3,4], the
11-amino acid peptide from the C-terminus of the precursor to
protein VI, pVI, and the viral DNA genome [3]. We determined crys-
tal structures of the AVP–pVIc complex at 1.6 Å resolution [2] and
of AVP in the absence of cofactors at 0.98 Å resolution [5]. Because
AVP is essential for synthesis of infectious virus, it is an attractive
target for antiviral therapy [6–9].
Our approach toward development of antiviral agents for ade-
novirus, more speciﬁcally inhibitors of AVP, was to use the crystal
structures and docking programs against the chemicals in a portionpeutics Program to identify compounds predicted to bind to sites
likely to be critical for AVP activity. In this report, we identify
and analyze a lead compound and two derivatives of it that inhib-
ited the enzymes.
2. Materials and methods
2.1. Structure-based drug design
The X-ray crystal structures of the 1.6 Å structure of the acti-
vated covalent AVP–pVIc complex (PDB ID: 1NLN) and the 0.98 Å
structure of AVP alone (PDB ID: 4EKF) were used for in silico
screening. To prepare the structures for site identiﬁcation, all
waters and heteroatoms were removed from the coordinate ﬁles.
Then, using Chimera (UCSF), mol2 ﬁles were generated utilizing
the highest occupancy alternate conformation side chains with
all hydrogens assigned based on default charge parameters. Then,
the hydrogens were stripped from the structures, and the DMS
module of Chimera was used to generate the molecular surface
for each protein. In order to identify potential sites on the surface,
the SPHGEN module of DOCK (version 5.0, UCSF) was run using a
1.4 Å probe on the molecular surface. The resultant sphere ﬁles
were converted to PDB format utilizing the DOCK module SHOW-
SPHERE, and then visual inspection of the spheres for complemen-
tarity in regions of the structures involved in cofactor binding or
activation was carried out. Sphere clusters residing within an 8 Å
radius of those speciﬁc regions of interest were compiled, one clus-
ter near the active site residues His54 and Cys122, another cluster
in a surface pocket that in the AVP–pVIc structure contains the
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dent validation of the site choices, Fpocket, an open source pocket
detection software package, was used to detect cavities from the
PDB ﬁles, with water and heteroatoms of AVP or AVP–pVIc com-
plexes removed. Visual inspection of the results of the query struc-
tures with embedded centers of pocket a-spheres revealed that in
the AVP structure, the NT-pocket was the second ranked among
the 12 identiﬁed in the Fpocket analysis. For the AVP–pVIc struc-
ture, the results list the active site pocket was the highest rank of
the 12 pockets that were identiﬁed in the Fpocket analysis. The
Fpocket results conﬁrmed our target choices.
The SHOWBOX module of DOCK was used to generate 4 Å
boxes in any direction around each sphere cluster ﬁle that was
then used as input for the GRID program, which calculates and
saves the information concerning the steric and electrostatic
environment within the box areas as mol2 ﬁles. DOCK 5.0 was
then used to screen approximately 140000 small molecules from
the National Cancer Institute/Developmental Therapeutics
Program (NCI/DTP) Open Chemical Repository (http://dtp.can-
cer.gov) within the grids, using the selected spheres as theoret-
ical binding sites. The small molecule output was ranked based
on intermolecular AMBER energy scoring (van der Waals plus
coulombic), contact scoring and bump ﬁltering. The resultant
ligand poses were then ranked by energy score with those in
the entire virtual library on a relative basis, and the top ranked
ligands were visually inspected for binding poses for each target.
The top 10 compounds from each target were obtained from the
NCI/DTP for testing the efﬁcacy as an inhibitor in biochemical
assays.
2.2. Materials
The gene for adenovirus serotype 2 proteinase, AVP, was
expressed in Escherichia coli and the resultant protein puriﬁed as
described previously [3,10]. pVIc (GVQSLKRRRCF) was purchased
from Invitrogen (Carlsbad, CA). pVIc concentrations were deter-
mined by titration of the cysteine residue with Ellman’s reagent
[11,12] using an extinction coefﬁcient of 14150 M1 cm1 at
412 nm for released thionitrobenzoate. TPCK-treated trypsin was
obtained from Worthington Biochemical Corporation, and papain
was obtained from Sigma Chemical Company. The NCI compounds
were obtained upon request to (http://dtp.cancer.gov). DDM
(n-Dodecyl-b-D-Maltopyranoside) was obtained from Anatrace.
The ﬂuorogenic substrates (Cbz-Leu-Arg-Gly-Gly-NH)2-Rhodamine
[3,13], (Pro-Arg-NH)2-Rhodamine [14,15], and (Phe-Arg-NH)2-Rho-
damine were synthesized as described.
2.3. AVP–pVIc complex formation
Disulﬁde-linked AVP–pVIc complexes were prepared by over-
night incubation at 4 C of 75 lM AVP and 75 lM pVIc in 20 mM
Tris–HCl (pH 8.0), 250 mM NaCl, 0.1 mM EDTA and 20 mM
b-mercaptoethanol. Under these conditions, Cys104 of AVP and
Cys100 of pVIc undergo oxidative condensation [16,17].Table 1
Testing of ﬁrst and second generation inhibitors.
NSC 36806 NSC 37
AVP IC50 = 0
AVP–pVIc IC50 = 18 lM IC50 = 2
Trypsin No inh
Papain No inh
AVP–pVIc
AVP
The assays are described in Section 2.2.4. Enzyme activity assays
All enzymatic assays were performed at 21 C in a Corning 96-
well half-area black ﬂat bottom plate. The reaction volume was
100 ll and Rhodamine-based ﬂuorogenic substrates were used.
The excitation and emission wavelengths were 496 and 523 nm,
respectively. Substrate hydrolysis was monitored every 10 s by
measuring the time-dependent increase in ﬂuorescence intensity
using a Tecan Saﬁre 2 plate reader. The initial rate relative ﬂuores-
cence intensity (RFI s1) was determined from a linear ﬁt of the
data and converted to nM s1 as described previously [18].
2.5. Inhibition of AVP–pVIc complexes by lead compound NSC 36806
AVP–pVIc complexes, 0.3 lM, were incubated with the indi-
cated concentrations of NSC 36806 in 5 mM NaCl, 20 mM Tris–
HCl (pH 8.0), 0.025% DDM and 0.01 mM DTT. After 9 min., 5 lM
substrate, (Cbz-Leu-Arg-Gly-Gly-NH)2-Rhodamine, was added
and the increase in ﬂuorescence monitored as a function of time.
2.6. Coarse screening of structural derivatives for enzyme inhibitors
The NCI compounds were dissolved in neat DMSO to a concen-
tration of 10 mM. A coarse screening of eight NCI compounds,
Table 2, was performed: AVP–pVIc complexes, 0.3 lM, were incu-
bated in 150 mM NaCl, 20 mM Tris–HCl (pH 8), 0.025% DDM, and
0.1 mM DTT with 40 lM NCI compound. After 9 min, enzyme
activity was assayed with the ﬂuorogenic substrate (Cbz-Leu-
Arg-Gly-Gly-NH)2-Rhodamine, 5 lM. Inhibition of AVP was as-
sayed the same way except that after the 9 min. incubation, pVIc
was added to 40 lM followed by an additional 9 min. of incubation
before measuring enzyme activity.
2.7. Determination of IC50
The IC50 values of compounds NSC 37248 and NSC 37249 with
AVP and with AVP–pVIc complexes were determined as described
in ‘‘Coarse screening for enzyme inhibitors’’ except that: the NaCl
concentration in the buffer was 5 mM instead of 150 mM, and
the pVIc concentration was 20 lM instead of 40 lM. The IC50 value
was determined by ﬁtting the dose–response curve to a four-
parameter logistic equation. The equation is:
m ¼ Vmin þ Vmax  Vmin
1þ ½IIC50
h in
where m is the observed initial rate, Vmin is the minimum initial rate,
Vmax is the maximum initial rate, [I] is the inhibitor concentration,
and n is the Hill exponent.
2.8. Competitive inhibition of AVP–pVIc complexes by NSC 37249
AVP–pVIc complexes, 0.3 lM, were incubated with the
indicated concentrations of NSC 37249 in 5 mM NaCl, 20 mM248 NSC 37249
.88 lM IC50 = 0.14 ± 0.06 lM
.1 lM IC50 = 0.49 ± 0.076 lM
ibition No inhibition
ibition No inhibition
Competitive inhibition Ki = 403 nM
Mixed inhibition Ki = 0.15 lM.
Table 2
Potential second generation inhibitors.
NSC
No.
Chemical structure IUPAC name
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2334 W.J. McGrath et al. / FEBS Letters 587 (2013) 2332–2339
Fig. 1. Surface map of AVP reveals potential drug targets. More than 45% of the
surface area of AVP contains potential targets for proteinase inhibitors. The
molecular surface of AVP (white) with the amino acid residues involved in
regulating enzyme activity shown in colors: Active site region (green), pVIc binding
region (magenta), DNA binding region (blue), residues common to pVIc or DNA
binding (yellow), and remainder of the activation pathway (red).
Table 2 (continued)
NSC
No.
Chemical structure IUPAC name
106720
S
O
O
NH
OF
F
N
NH
O F
F
N
2-(Dihexylamino)-N-[4-[4-[[2-(dihexylamino)-2,2-
diﬂuoroacetyl]amino]phenyl] sulfonylphenyl]-2,2-diﬂuoroacetamide
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four, different concentrations of substrate(Cbz-Leu-Arg-Gly-Gly-
NH)2-Rhodamine, were added and enzyme activity assayed. The
initial rate data were entered into SigmaPlot Kinetic Module (Jan-
del Scientiﬁc) and analyzed for various inhibition models. The best
ﬁtting model was competitive inhibition with a Ki of 0.43 lM. The
concentrations of (Cbz-Leu-Arg-Gly-Gly-NH)2-Rhodamine were
2.5, 5, 10, and 20 lM.
2.9. Mixed inhibition of AVP by NSC 37249
AVP, 0.15 lM, was incubated with different concentrations of
NSC 37249 and pVIc for 10 min at 21 C in 5 mM NaCl, 20 mM
Tris–HCl (pH 8), 0.025% DDM and 0.1 mM DTT. Substrate, (Cbz-
Leu-Arg-Gly-Gly-NH)2-Rhodamine, was then added to the reaction
mixture to 5 lM, and the rate of substrate hydrolysis measured as
described above. The concentrations of NSC 37249 were 0, 0.05,
0.075, 0.1, 0.2, and 0.4 lM. The concentrations of pVIc were 1.25,
2.5, 5, 10, and 20 lM. The initial rate data were entered into the
SigmaPlot Kinetic Module and analyzed for various inhibitionmod-
els. The best ﬁtting model was mixed inhibition with a Ki of
0.15 lM.
2.10. Selectivity and speciﬁcity experiments with trypsin and papain
Trypsin, 20 pM, was incubated with increasing amounts of com-
pound NSC 37249 for 10 min at 21 C in 25 mM HEPES (pH 7.5),
1 mM CaCl2. Enzyme activity was measured by monitoring the rate
of substrate hydrolysis, 10 lM (Ile-Pro-Arg-NH)2-Rhodamine, as a
function of time. The rates were then normalized to the rate in
the absence of inhibitor and reported as % activity. A similar assay
was performed with papain with the following exceptions: the
concentration of papain was 0.18 lM, the assay buffer was
25 mM sodium acetate, pH 5, 1 mM DTT, and the substrate was
10 lM (Phe-Arg-NH)2-Rhodamine.
3. Results
3.1. The lead compound
A comparison of the structures of the inactive AVP structure and
active AVP–pVIc complex structure revealed a number of differ-
ences which could be considered as targets for drug interactions,
Fig. 1. Inspection of the surface of the AVP–pVIc complex indicates
that the N- and C-termini of pVIc are bound in pockets, Fig. 2B.
When comparing these sites to those regions on the surface of
the AVP structure, only the N-terminal binding pocket for pVIc,
abbreviated NT-pocket, is fully formed, Fig. 2A. The C-terminal
binding pocket for pVIc, abbreviated CT-pocket, therefore must
be induced upon the binding of pVIc. We predicted that a drugbinding in the NT-pocket would prevent the binding of pVIc to
AVP and hence prevent the activation of AVP. To see if the
NT-pocket is a legitimate druggable site, we mutated the N-termi-
nal amino acid of pVIc to an Ala. The Kd for the binding of wild-type
pVIc to AVP is 4.4 lM [19]; the Kd for the mutant is at least an order
of magnitude higher. Therefore, this pocket is a legitimate site.
Structure-based drug design on the NT-pocket in AVP yielded
several hundred potential inhibitors. The highest energy score
ranked hit identiﬁed by DOCK was the compound NSC 36806,
Fig. 2G. The favorable binding pose predicted in the NT-pocket is
shown in Figs. 2E and Fig. 3A. At the same time, we also used DOCK
to ﬁnd ligands predicted to bind to the active site region of the
AVP–pVIc complex, Fig. 2D. Here, using identical parameters for
DOCKing, we noticed that NSC 36806 was among the top 90 hits.
The predicted binding pose of NSC 36806 in the active site of the
AVP–pVIc complex is shown in Figs. 2F and Fig. 3B.
We tested NSC 36806 as an inhibitor of AVP. AVP was incubated
with different concentrations of the compound and then pVIc and
(Cbz-Leu-Arg-Gly-Gly-NH)2-Rhodamine [3,13] were added and the
rate of substrate hydrolysis determined. The data were complex
and difﬁcult to interpret, possibly because the compound was
binding to more than one site on AVP (data not shown). We also
tested NSC 36806 as an inhibitor of AVP–pVIc complexes. Here,
Fig. 2. From target to inhibitor: (A) Surface of AVP (turquoise) with NT-pocket colored in dark gray and the active site in red. (B) Surface of the AVP–pVIc complex (yellow)
with the CT-pocket colored in mauve. pVIc is colored. (C) Surface of AVP with energetically favorable ligand atoms (spheres) colored in orange. (D) Surface of the AVP–pVIc
complex with energetically favorable ligand atoms (spheres) colored in green. (E) Surface of AVP with the inhibitor NSC 36806 bound in the NT-pocket. (F) Surface of the AVP–
pVIc complex with the inhibitor NSC 36806 bound in the active site. (G) The structure of the lead inhibitor NSC 36806, in ball and stick form with carbon colored green,
nitrogen colored blue, oxygen colored red, sulfur colored yellow and hydrogens colored white. (C40H44N8O8S2): 2,21-dithia-7,10,13,16,26,29,32,35-octaazaheptacyclo-
[34.2.2.23,6.210,13.217,20.222,25.2 29,32] pentaconta-1(38),3,5,17,19,22,24,36,39,43,45,49-dodecaene-8,15,27,34-tetrone 2,2,21,21-tetraoxide.
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Fig. 3. Predicted binding pose of NSC 36806 in the NT-pocket of AVP and in the
active site of the AVP–pVIc complex. (A) Binding of NSC 36806 in the NT-pocket of
AVP. For NSC 36806, carbon is magenta, nitrogen is blue, sulfur is orange and
oxygen is red. The surface in red contains amino acid residues that are within 5 Å of
NSC 36806. (B) Binding of NSC 36806 in the active site of the AVP–pVIc complex. For
NSC 36806, carbon is yellow, nitrogen is blue, sulfur is orange and oxygen is red.
Two amino acids involved in catalysis, C122 and H54, are colored green. The surface
in white contains amino acid residues that are within 5 Å of NSC 36806.
Fig. 4. Inhibition of AVP–pVIc complexes by NSC 36806. AVP–pVIc complexes,
0.3 lM, were pre-incubated with increasing amounts of NCI 36806 for 9 min at
21 C in 5 mM NaCl, 20 mM Tris–HCl (pH 8), 0.025% DDM, and 0.1 mM DTT. Enzyme
activity was measured by monitoring the rate of substrate hydrolysis, 5 lM (Cbz-
Leu-Arg-Gly-Gly-NH)2-Rhodamine, as a function of time. The IC50, 18 lM, was
obtained by ﬁtting the experimental initial rate data to a four-parameter logistic
equation.
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should not be able to bind to the NT-pocket We incubated different
concentrations of the compound with the enzyme and then added
the ﬂuorogenic substrate (Cbz-Leu-Arg-Gly-Gly-NH)2-Rhodamine
[3,13] and measured the rate of substrate hydrolysis. Clearly, the
compound inhibited AVP–pVIc complexes, Fig. 4. The IC50 was
18 lM, Table 1. We tested NSC 36806 as a promiscuous inhibitor
[20–23] and found it did not inhibit the activity of trypsin (data
not shown).
3.2. Structural derivative compounds
Because the DOCK pose of NSC 36806 indicated a signiﬁcant
portion of the compound was not interacting with AVP and, also,
its molecular weight was slightly high, we initiated a substructure
search of the NCI repository and found 8 compounds structurally
related to NSC 36806. These compounds were not among the com-
pounds used in the DOCKing analysis. Their structures are shown
in Table 2; essentially all these compounds are derivatives of acet-
amidophenyl sulfonylphenylacetamides. We tested all 8 com-
pounds for inhibition of AVP and of AVP–pVIc complexes. Four of
the compounds were found to inhibit either the activation of AVP
or the activity of AVP–pVIc complexes – NSC 37248, NSC 37249,
NSC 106702, and NSC 106721. Two of the compounds, NSC
37248 and NSC 37249 were effective inhibitors.
Structurally, NSC 37249 is similar to NSC 36806. In NSC 36806,
there are piperazine-based cyclic joinings of the two acetamid-
ophenyl sulfonylphenyl acetamides, while in NSC 37249, each
acetamide moiety is derivatized with cyclohexylcyclohexamine.
Since NSC 36806 was predicted to bind to the NT-pocket in AVP
and to the active site in AVP–pVIc complexes, one might expect
NSC 37249 would bind to those same sites. The data, shown in
Fig. 5B, are consistent with this prediction of two sites. The IC50
value with AVP (0.14 lM) is different from the IC50 value with
AVP–pVIc complexes (0.49 lM), Table 1. Since NSC 37249 was pre-
dicted to bind only to the active site in AVP–pVIc complexes, one
might predict NSC 37249 would be a competitive inhibitor. The
data, presented in the form of a Dixon plot in Fig. 5C, indicate that
NSC 37249 is indeed a competitive inhibitor of AVP–pVIc com-
plexes with a Ki of 0.40 lM, Table 1. Similar sets of experiments
were done with AVP, and the result indicated mixed inhibition
with a Ki of 0.15 lM, Fig. 5D, Table 1.
How speciﬁc is NSC 37249 for AVP and AVP–pVIc complexes?
We ﬁrst determined whether NSC 37249 inhibited trypsin, the
canonical serine proteinase. At concentrations of NSC 37249 up
to 18 lM, concentrations that would have inhibited AVP and
AVP–pVIc complexes, no inhibition was observed, Fig. 6. This result
also indicates that NSC 37249 is not a promiscuous inhibitor, a
compound that binds and aggregates most anything thereby gen-
erating false positives [20–23]. Next, we determined whether
NSC 37249 inhibited the canonical cysteine proteinase papain.
Again, at concentrations of NSC 37249 up to 50-fold the Ki for
AVP, no inhibition was observed, Fig. 6.
4. Discussion
During an adenovirus infection, two forms of AVP are present,
one early and one late. AVP is initially synthesized in an inactive
form. The NT-pocket, where the N-terminus of pVIc binds, is a
druggable target. A compound binding there should prevent pVIc
from binding and thus inhibit the activation of the enzyme. Paren-
thetically, the structure of the NT-pocket in AVP is the same in the
AVP–pVIc complex. One reason AVP is inactive is that its active site
is structurally different from that in AVP–pVIc, the active form of
the enzyme. Thus, the active site of AVP was not considered for
drugging. However, it is a druggable site in the AVP–pVIc complex.
Fig. 5. Assays of potential second generation proteinase inhibitors. (A) Coarse screen of 8 NCI compounds whose structures are shown in Table 2. The inhibition assays are
described in Section 2. All the initial rates of enzyme activity were normalized to the initial rates in the absence of inhibitor and plotted on the same graph for comparison.
The control was the activity of AVP (gray) or AVP–pVIc complexes (black) in the absence of inhibitor. (B) IC50 values for the inhibition of AVP and AVP–pVIc complexes by NSC
37249. Assays were performed as described in Section 2. The IC50 value for AVP was 0.14 lM, and for AVP–pVIc complexes it was 0.49 lM. AVP (h) and AVP–pVIc complexes
(s). (C) Competitive inhibition of AVP–pVIc complexes by NSC 37249. AVP–pVIc complexes were incubated with the indicated concentrations of NSC 37249 and, after 9 min,
four, different concentrations of substrate were added and enzyme activity assayed, as described in Section 2. The data are presented in a Dixon plot yielding a Ki of 0.403 lM.
The concentrations of (Cbz-Leu-Arg-Gly-Gly-NH)2-Rhodamine were 2.5 lM (d), 5 lM (r), 10 lM (j), and 20 lM (}). D. Dixon plot of NSC 37249 inhibition. Data used for
graph are from assays where AVP was incubated simultaneously with NSC 37249 and cofactor pVIc. pVIc concentrations were 1.25 (d), 2.5 (4), 5 (j), 10 (}), and 20 ( ) lM.
AVP activity assays were performed as described in Section 2. The experimental initial rates were entered into SigmaPlot Kinetic Module and analyzed for various inhibition
models. The best model was mixed inhibition with a Ki of 0.15 lM.
2338 W.J. McGrath et al. / FEBS Letters 587 (2013) 2332–2339A drug binding in the active site of the AVP–pVIc complex may
interfere with substrate binding thereby affecting the activity of
the enzyme. Our docking studies revealed a compound predicted
to bind in the NT-pocket in AVP and in the active site of the
AVP–pVIc complex, and this compound inhibited the enzyme.
Searches of structural variants of this lead inhibitor identiﬁed
two other, even more effective, compounds. Each of these com-
pounds is predicted to bind to two different sites, one in AVP and
the other in the AV-pVIc complex. It may be that we have identiﬁed
a compound that both inhibits a crucial step early in infection and
a crucial step late in infection.
Compounds like NSC 36806 or derivatives of it are potentially
unique antiviral agents in that the virus may have difﬁculty in
becoming resistant to it. The two sites on the proteinase
predicted to bind to NSC 36806, the NT-pocket and the active site,
are at the ends of a 62 amino acid long activation path [5].
Because these two binding sites are quite far from each other, a
minimum of two mutations may be required for a virus to be-
come resistant. The probability of two independent mutations
occurring at speciﬁc sites within 615 bases on the same DNAmolecule is quite low. Secondly, because the two binding sites
are connected by an activation path, a mutation leading to resis-
tance at one site may affect the functioning of the activation path
leading to the other site, thereby decreasing the probability of
resistance arising even more [24,25]. This is not unlike combina-
tion therapy, but, instead of two compounds interacting with two,
different sites, it is one compound interacting with two, different
sites.
The apparent speciﬁcity of NSC 37249 was surprising. At con-
centrations 50-fold higher than that which would inhibit AVP or
AVP–pVIc complexes by more than 90%, the compound did not
inhibit trypsin or papain. This result was surprising as the crystal
structure of AVP–pVIc complexes indicates the four amino acids
involved in catalysis are in identical positions to those in papain
[1,2]. However, in examining how NSC 36806 docked to the active
site of the AVP–pVIc complex structure aligned to a papain struc-
ture active site, several regions within the active site groove
predicted to interact with NSC 36806 in the AVP are absent in
the papain active site, and this may be the origin of the apparent
selectivity of NSC 37249.
Fig. 6. Selectivity of NSC 37249, assays with trypsin, the canonical serine proteinase
and papain, the canonical cysteine proteinase. The inhibition assays are described in
Section 2. The rates of substrate hydrolysis were normalized to the rate in the
absence of inhibitor and are reported as % activity. Trypsin (d) and papain (h).
W.J. McGrath et al. / FEBS Letters 587 (2013) 2332–2339 2339Much more needs to be done in characterizing these inhibitors.
Especially important would be the structures of co-crystals of
inhibitors and enzymes to see if the binding poses are those pre-
dicted by DOCK and as an aide in the design of additional com-
pounds for testing. At the very least, however, these molecules
should provide a scaffold from which to build more speciﬁc second
generation inhibitors.
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